Mosaic ImmunoEngineering (OTCMKTS:CPMV) Posts Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMV) posted its quarterly earnings data on Tuesday. The company reported ($0.03) EPS for the quarter, Zacks reports.

Mosaic ImmunoEngineering Price Performance

CPMV remained flat at $0.54 during trading on Tuesday. The company’s stock had a trading volume of 52 shares, compared to its average volume of 969. Mosaic ImmunoEngineering has a 12-month low of $0.10 and a 12-month high of $1.13. The business’s fifty day simple moving average is $0.71 and its two-hundred day simple moving average is $0.84. The stock has a market capitalization of $3.91 million, a price-to-earnings ratio of -3.60 and a beta of 0.11.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.